Takeda Pharmaceutical beats Q2FY25 estimates with strong growth from Growth and Launch Products. The company is raising FY25 guidance despite expected H2FY25 challenges.
What is covered in the Full Insight:
Q2FY25 Financial Performance
FY25 Guidance Revision
Performance of Key Drugs
New Product Launches
Pipeline Developments
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.